Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-001790-41
    Sponsor's Protocol Code Number:2215-CL-0201
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2016-06-28
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2015-001790-41
    A.3Full title of the trial
    A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in
    Patients Not Eligible for Intensive Induction Chemotherapy
    Étude multicentrique randomisée ouverte de phase 2/3, à 3 bras de traitement suivant un plan expérimental en 2 étapes, comparant l’ASP2215 (Gilteritinib) en monothérapie, l’association de l’ASP2215 avec l’Azacitidine, et l’Azacitidine seule pour le
    traitement des leucémies aiguës myéloïdes de novo associées à une mutation de FLT3 chez les patients non éligibles à un traitement d’induction par chimiothérapie intensive
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in
    Patients Not Eligible for Intensive Induction Chemotherapy
    Étude multicentrique randomisée ouverte de phase 2/3, à 3 bras de traitement suivant un plan expérimental en 2 étapes, comparant l’ASP2215 (Gilteritinib) en monothérapie, l’association de l’ASP2215 avec l’Azacitidine, et l’Azacitidine seule pour le
    traitement des leucémies aiguës myéloïdes de novo associées à une mutation de FLT3 chez les patients non éligibles à un traitement d’induction par chimiothérapie intensive
    A.4.1Sponsor's protocol code number2215-CL-0201
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAstellas Pharma Global Development, Inc. (APGD)
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAstellas Pharma Global Development, Inc. (APGD)
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAstellas Pharma Europe B.V.
    B.5.2Functional name of contact pointService Desk - Global Clinical Dev.
    B.5.3 Address:
    B.5.3.1Street AddressSylviusweg 62
    B.5.3.2Town/ cityLeiden
    B.5.3.3Post code2333 BE
    B.5.3.4CountryNetherlands
    B.5.4Telephone number+31715455050
    B.5.5Fax number+31715455840
    B.5.6E-mailcontact@nl.astellas.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameASP2215
    D.3.2Product code ASP2215
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGILTERITINIB
    D.3.9.2Current sponsor codeASP2215
    D.3.9.4EV Substance CodeSUB177203
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Vidaza 25 mg/mL powder for suspension for injection
    D.2.1.1.2Name of the Marketing Authorisation holderCelgene
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameVidaza
    D.3.4Pharmaceutical form Powder for suspension for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    Subcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAZACITIDINE
    D.3.9.1CAS number 320-67-2
    D.3.9.4EV Substance CodeSUB05624MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
    Leucémies aiguës myéloïdes (LAM) de novo associées à une mutation de FLT3 chez les patients non éligibles à un traitement d’induction par chimiothérapie intensive
    E.1.1.1Medical condition in easily understood language
    AML is cancer of myeloid line of blood cells characterized by rapid growth of abnormal white blood cells that accumulate in bone marrow and interfere with production of normal blood cells.
    LAM est un cancer de la lignée myéloïde des cellules sanguines caractérisé par un envahissement médullaire de cellules immatures dû à un blocage de maturation des globules blancs dns la moelle osseuse
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.0
    E.1.2Level LLT
    E.1.2Classification code 10000886
    E.1.2Term Acute myeloid leukemia
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Determine the efficacy superiority of ASP2215 and/or ASP2215 plus azacitidine versus azacitidine as measured by overall survival (OS).
    Déterminer la supériorité de l'ASP2215 et/ou de l'ASP2215 plus azacitidine seule, comparées à l'azacitidine, sur la survie globale (SG).
    E.2.2Secondary objectives of the trial
    Determine the efficacy superiority of ASP2215 and/or ASP2215 plus azacitidine versus azacitidine as measured by event-free survival (EFS).
    Déterminer la supériorité de l'ASP2215 et/ou de l'ASP2215 plus azacitidine, comparées à l'azacitidine seule, sur survie sans événement (SSE).
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Retrospective PGx Sub-study (Optional)
    E.3Principal inclusion criteria
    1. Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written informed consent and privacy language as per national regulations (e.g., Health Insurance Portability and Accountability Act [HIPAA] Authorization for United States [US] sites) must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).
    2. Subject is considered an adult according to local regulation at the time of obtaining informed consent.
    3. Subject has a diagnosis of previously-untreated AML according to World Health Organization (WHO) classification [Swerdlow et al, 2008] as determined by pathology review at the treating institution.
    4. Subject is positive for FLT3 mutation (ITD or TKD [D835/I836] mutation) in bone marrow or whole blood as determined by central laboratory.
    5. Subject is ineligible for intensive induction chemotherapy by meeting at least 1 of the following criteria:
    a. Subject is ≥ 75 years of age.
    b. Subject has any of the following comorbidities:
    i. Congestive heart failure or ejection fraction (Ef) ≤ 50%;
    ii. Creatinine > 2 mg/dL (177 μmol/L), dialysis or prior renal transplant;
    iii. ECOG performance status ≥ 3;
    iv. Prior or current malignancy that does not require concurrent treatment;
    v. Subject has received a cumulative anthracycline dose above 400 mg/m2.
    6. Subject must meet the following criteria as indicated on the clinical laboratory tests:
    ● Serum AST and ALT ≤ 2.5 x upper limit of normal (ULN)
    ● Serum total bilirubin ≤ 1.5 x ULN
    ● Serum potassium ≥ lower limit of normal (LLN)
    ● Serum magnesium ≥ LLN
    7. Subject is suitable for oral administration of study drug.
    8. Female subject must either:
    ● Be of nonchildbearing potential:
    o Postmenopausal (defined as at least 1 year without any menses) prior to
    screening, or
    o Documented surgically sterile or status posthysterectomy (at least 1 month
    prior to screening)
    ● Or, if of childbearing potential,
    o Agree not to try to become pregnant during the study and for 45 days after the final study drug administration
    o And have a negative urine pregnancy test at screening
    o And, if heterosexually active, agree to consistently use 2 forms of effective
    contraception per locally accepted standards, 1 of which must be a barrier
    method, starting at screening and throughout the study period and for 45 days
    after the final study drug administration.
    9. Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 45 days after the final study drug administration.
    10. Female subject must not donate ova starting at screening and throughout the study period, and for 45 days after the final study drug administration.
    11. Male subject and their female partners who are of childbearing potential must be using 2 forms of effective contraception per locally accepted standards, 1 of which must be a barrier method, starting at screening and continue throughout the study period, and for 105 days after the final study drug administration.
    12. Male subject must not donate sperm starting at screening and throughout the study period and for 105 days after the final study drug administration.
    13. Subject agrees not to participate in another interventional study while on treatment.
    Waivers to the inclusion criteria will NOT be allowed.
    1. Formulaire de consentement éclairé écrit approuvé par le comité d'éthique (CPP, comité de protection des personnes) et termes de confidentialité conformes aux réglementations locales (par exemple, autorisation HIPAA [Insurance Portability and Accountability Act] aux États-Unis), fournis par le patient ou son représentant légal avant toute activité liée à l'étude (y compris le retrait des médicaments interdits, si applicable).
    2. Patient adulte d'après les réglementations locales au moment de l'obtention du formulaire de consentement éclairé.
    3. Diagnostic de LAM non traitée auparavant d'après la classification de l'OMS (Organisation Mondiale de la Santé), déterminé par l'examen anatomo-pathologique effectué dans l'hôpital.
    4. Présence de mutations de FKT3 (mutation ITD ou TKD [D835/I836]) mises en évidence dans la moelle osseuse ou le sang du patient, d'après l'évaluation du laboratoire central.
    5. Inéligibilité du patient pour recevoir une chimiothérapie d'induction intensive, fondée sur au moins 1 des critères suivants :
    a. Âge ≥ 75 ans.
    b. Présence d'une des comorbidités suivantes :
    i. Insuffisance cardiaque congestive ou fraction d'éjection (FE) ≤ 50 % ;
    ii. Créatininémie > 2 mg/dl (177 μmol/l), dialyse ou antécédents de greffe rénale ;
    iii. Indice de performances ECOG ≥ 3 ;
    iv. Cancer en cours ou antérieur ne nécessitant pas de traitement concomitant ;
    v. Administration antérieure d'une dose cumulative d'anthracycline supérieure à 400 mg/m2.
    6. Présence des critères suivants, indiqués sur les résultats des analyses biologiques cliniques :
    ● Taux sériques d'ASAT et d'ALAT ≤ 2,5 la limite supérieure de la normale (LSN)
    ● Taux sériques de bilirubine totale ≤ 1,5 LSN
    ● Taux sériques de potassium ≥ la limite inférieure de la normale (LIN)
    ● Taux sériques de magnésium ≥ LIN
    7. Capacité du patient à recevoir le médicament à l'étude par voie orale.
    8. Les femmes participant à l'étude doivent être dans une des catégories suivantes :
    - Non aptes à procréer :
    ● Ménopause avérée (définie comme au moins 1 an sans règles) avant la sélection, ou
    ● Antécédents de stérilisation chirurgicale documentée ou statut de post-hystérectomie (au moins 1 mois avant la sélection)
    - Ou, si aptes à procréer,
    ● Consentement à éviter toute grossesse pendant l'étude et les 45 jours après l'administration finale du médicament à l'étude
    ● Test urinaire de grossesse négatif lors de la sélection
    ● Si activité hétérosexuelle, consentement à utiliser de façon constante 2 moyens efficaces de contraception conformément aux normes localement acceptées, dont 1 doit être une méthode mécanique (« barrière »), en commençant à la sélection et pendant toute la période d'étude et les 45 jours après l'administration finale du médicament à l'étude.
    9. Pour les femmes participant à l'étude, consentement de ne pas allaiter, en commençant à la sélection et pendant toute la période d'étude et les 45 jours après l'administration finale du médicament à l'étude.
    10. Pour les femmes participant à l'étude, consentement de ne pas effectuer de dons d'ovules, en commençant à la sélection et pendant toute la période d'étude et les 45 jours après l'administration finale du médicament à l'étude.
    11. Pour les hommes participant à l'étude et leurs partenaires féminines en âge de procréer, utilisation de 2 formes efficaces de contraception conformément aux normes localement acceptées, dont 1 doit être une méthode mécanique (« barrière »), en commençant à la sélection et pendant toute la période d'étude et les 105 jours après l'administration finale du médicament à l'étude.
    12. Pour les hommes participant à l'étude, consentement de ne pas effectuer de dons de sperme, en commençant à la sélection et pendant toute la période d'étude et les 105 jours après l'administration finale du médicament à l'étude.
    13. Consentement à ne pas participer ç une autre étude interventionnelle pendant le traitement.
    AUCUNE dérogation aux critères d'inclusion ne sera tolérée.
    E.4Principal exclusion criteria
    1. Subject was diagnosed as acute promyelocytic leukemia (APL).
    2. Subject has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
    3. Subject has received previous therapy for AML, with the exception of the following:
    ● Emergency leukapheresis
    ● Hydroxyurea for ≤ 14 days
    ● Preemptive treatment with retinoic acid prior to exclusion of APL ≤ 7 days
    ● Growth factor or cytokine support
    ● Steroids for the treatment of hypersensitivity or transfusion reactions
    4. Subject has clinically active central nervous system leukemia.
    5. Subject has been diagnosed with another malignancy that requires concurrent treatment or hepatic malignancy regardless of need for treatment.
    6. Subject has clinically significant coagulation abnormality unless secondary to AML in the opinion of the investigator.
    7. Subject has had major surgery within 4 weeks prior to the first study dose.
    8. Subject has radiation therapy within 4 weeks prior to the first study dose.
    9. Subject requires treatment with concomitant drugs that are strong inducers of CYP3A4.
    10. Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P-gp with the exception of drugs that are considered absolutely essential for the care of the subject.
    11. Subject requires treatment with concomitant drugs that target serotonin 5HT1R or 5HT2BR or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject.
    12. Subject has congestive heart failure classified as New York Hearth Association Class IV.
    13. Subject with mean Fridericia-corrected QT interval (QTcF) > 450 ms at screening based on central reading.
    14. Subject with Long QT Syndrome at screening.
    15. Subject has known pulmonary disease with diffusion capacity of lung for carbon monoxide (DLCO) ≤ 65%, forced expiratory volume in the first second (FEV1) ≤ 65%, dyspnea at rest or requiring oxygen or any pleural neoplasm.
    16. Subject has an active uncontrolled infection. If an infection is present, the patient must be receiving definitive therapy and have no signs of progressing infection. Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
    17. Subject is known to have human immunodeficiency virus infection.
    18. Subject has active hepatitis B or C or other active hepatic disorder.
    19. Subject has any condition which, in the investigator’s opinion, makes the subject unsuitable for study participation.
    Waivers to the exclusion criteria will NOT be allowed.
    Un patient ne pourra pas participer à l'étude s'il présente un des critères suivants :
    1. Diagnostic de leucémie aiguë promyélocytaire (LAP).
    2. Présence d'une leucémie BCR-ABL-positive (leucémie myéloïde chronique en crise blastique).
    3. Antécédents de traitement contre la LAM, à l'exception des traitements suivants :
    ● Leucophérèse en urgence
    ● Hydroxyurée pendant 14 jours ou moins
    ● Traitement préemptif par acide rétinoïque avant l'exclusion d'une Leucémie à Promyélocytes (LAP) pendant 7 jours ou moins
    ● Traitement par facteurs de croissance ou cytokines
    ● Corticoïdes pour le traitement des réactions d'hypersensibilité ou des réactions aux transfusions
    4. Leucémie cliniquement active au niveau du système nerveux central.
    5. Diagnostic d'un autre cancer nécessitant un traitement concomitant ou cancer hépatique quelle que soit la nécessité de traitement.
    6. Anomalies cliniquement significatives du bilan de la coagulation sauf si secondaires à la LAM selon le médecin-investigateur.
    7. Antécédents d'intervention chirurgicale majeure dans les 4 semaines précédant la première dose de médicament à l'étude.
    8. Antécédents de radiothérapie dans les 4 semaines précédant la première dose de médicament à l'étude.
    9. Nécessité d'un traitement concomitant avec des médicaments constituant des inducteurs puissants du CYP3A4.
    10. Nécessité d'un traitement concomitant avec des médicaments constituant des inducteurs ou des inhibiteurs puissants du P-gp, sauf les médicaments considérés comme absolument essentiels pour la prise en charge du patient.
    11. Nécessité d'un traitement concomitant avec des médicaments ciblant les récepteurs de sérotonine 5HT1R ou 5HT2BR ou le récepteur non spécifique sigma, sauf les médicaments considérés comme absolument essentiels pour la prise en charge du patient.
    12. Insuffisance cardiaque congestive, de classe IV, selon la classification de la New York Hearth Association.
    13. Intervalle QT moyen corrigé selon Fridericia (QTcF) > 450 ms à la sélection, d'après l'interprétation du laboratoire central.
    14. Présence d'un syndrome du QT long à la sélection.
    15. Pneumopathie connue avec capacité de diffusion des poumons pour le monoxyde de carbone (DLCO) ≤ 65 %, volume expiratoire maximum seconde (VEMS) ≤ 65 %, dyspnée de repos ou nécessitant de l'oxygène ou toute néoplasie pleurale.
    16. Infection non contrôlée active. En cas d'infection, le patient doit recevoir un traitement radical et ne pas présenter de signes de progression de l'infection. Par définition, une infection progressive est une instabilité hémodynamique imputable à une septicémie ou l'apparition de nouveaux symptômes, l'aggravation de signes cliniques ou des données radiographiques imputables à l'infection. Une fièvre persistante sans autres signes ou symptômes ne sera pas interprétée comme une infection progressive.
    17. Infection connue à virus de l'immunodéficience humaine.
    18. Hépatite B ou C active ou autre affection hépatique active.
    19. Présence d'une pathologie qui, d'après le médecin-investigateur, ne permet pas au patient de participer à l'étude.
    AUCUNE dérogation aux critères de non inclusion ne sera accéptée.
    E.5 End points
    E.5.1Primary end point(s)
    - Overall Survival
    Survie Globale
    E.5.1.1Timepoint(s) of evaluation of this end point
    Please refer to section E.5.1 and also the protocol.
    Voir le protocole et la section E.5.1 de la formulaire EudraCT
    E.5.2Secondary end point(s)
    Key Secondary Efficacy Endpoint:
    - Event-free survival

    Secondary Efficacy Endpoints:
    - Best Response
    - Leukemia-free survival
    - Duration of remission
    - Patient reported fatigue from BFI
    Safety Endpoints:
    - AEs
    - Clinical laboratory results
    - Vital sign measurements
    - Ophthalmology assessments
    - ECGs
    - ECOG performance scores
    Critère d’évaluation secondaire fondamental de l'efficacité :
    • Survie Sans Evénement (SSE)

    Critères d’évaluation secondaires de l'efficacité :
    • Meilleure réponse
    • Survie Sans Leucémie (SSL)
    • Durée de la rémission
    • Fatigue rapportée par le patient, d'après le questionnaire BFI

    Critères d’évaluation de la tolérance :
    • Evénement Indésirable
    • Résultats d'analyses biologiques cliniques
    • Mesure des signes vitaux
    • Examens ophtalmologiques :
    • ECG
    • Scores de performances ECOG
    E.5.2.1Timepoint(s) of evaluation of this end point
    Please refer to section E.5.2 and also the protocol.
    Voir le protocole et la section E.5.2 de la formulaire EudraCT
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned15
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA63
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Belgium
    Canada
    France
    Germany
    Italy
    Japan
    Korea, Republic of
    Poland
    Spain
    Taiwan
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    last subject last visit
    LSLV
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months2
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months3
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 1623
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 180
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Informed consent must be obtained from the subject or
    legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state59
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 734
    F.4.2.2In the whole clinical trial 1803
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    After completion of the trial, provisions will be made for participants who continue to derive benefit on their assigned treatment arm based on the investigator’s assessment.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-06-22
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-05-12
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 18:38:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA